Clinical Trial Update: Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2) [Phase 3]

View source ↗

Summary

A Phase 3 non-inferiority trial comparing Mylan's insulin glargine to Lantus in Type 2 diabetes has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (insulin glargine)
• Lantus (insulin glargine)

Snippet

Sponsor: Mylan Inc. | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2020-08-13